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OBJECTIVE — To evaluate the impact of continuous glucose monitoring (CGM) on quality
of life (QOL) among individuals with type 1 diabetes.
RESEARCH DESIGN AND METHODS — In a multicenter trial, 451 children and
adults with type 1 diabetes were randomly assigned to CGM treatment or the control group.
Generic and diabetes-speciﬁc QOL questionnaires were completed at baseline and 26 weeks by
all participants and parents of participants 18 years old, and the CGM satisfaction scale was
completed by the CGM group (participants and parents) at 26 weeks.
RESULTS — After 26 weeks, QOL scores remained largely unchanged for both the treatment
and the control group, although there was a slight difference favoring the adult CGM group on
several subscales (P  0.05). There was substantial satisfaction with CGM technology after 26
weeks among participants and parents.
CONCLUSIONS — Baseline QOL was high, and the measures showed little change with
CGM use, although a high level of CGM satisfaction was reported.
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I
ntheJuvenileDiabetesResearchFoun-
dation (JDRF) Continuous Glucose
Monitoring (CGM) trial, real-time
CGM improved glycemia for adults with
type 1 diabetes with entry A1C 7.0%
(1–3), and more frequent CGM use was
associated with a greater reduction in
A1C in all age-groups (2). Participants
withA1C7.0%atenrollmentwhoused
CGMmaintainedlowA1Clevelsmoreof-
ten than those who used standard blood
glucose monitoring (BGM) and also had
reduced biochemical hypoglycemia (3).
This analysis assesses change in quality of
life (QOL) among adults and children




METHODS— The protocol was ap-
proved by the institutional review boards
of the participating centers. Written
informed consent was obtained from
subjects aged 18 years and from par-
ents/guardians of minors; subjects aged
18 years provided written assent. The
study is listed on www.clinicaltrials.gov
(NCT00406133). Study procedures have
been described elsewhere (1–3). In brief,
451 individuals with type 1 diabetes were
randomized to the CGM treatment group
(n  122, 18 years old; n  110, 18
years old) or to the control group (n 
106, 18 years old; n  113, 18 years
old).CGMsubjectswereinstructedtouse
the CGM daily if possible; subjects in the
control group were instructed to perform
BGM 4 times per day. There were six
scheduled visits and one scheduled call
between visits to review glucose data and




of QOL were conducted at baseline and
26 weeks for all participants and parents
of participants 18 years old. Partici-
pants 18 years old completed the Hy-
poglycemia Fear Survey (HFS) (4–6),
Problem Areas In Diabetes (PAID) scale
(7),andSocialFunctioningHealthSurvey
(SF-12) version 2 (8). HFS includes ques-
tions about hypoglycemia fear (worry
subscale) and behaviors to prevent low
blood glucose (behavior subscale) (5).
PAID assesses psychosocial adjustments
relatedtodiabetesandincludesquestions
about anger, interpersonal distress, and
frustration with diabetes treatment (7).
SF-12 includes the mental component
summary (MCS) and physical component
summary(PCS)(8).Participants18years
of age completed the HFS worry subscale
(4,6) and selected subscales from the Pedi-
atric Quality of Life Inventory (PedsQL)-
Generic and Type 1 Diabetes Module
developed by J.W. Varni et al. (9,10). Par-
ents of participants 18 years of age com-
pleted the HFS worry subscale (4,5), the
PAID-Parent (PAID-P) survey evaluating
parental burden associated with diabetes
care (11), and parent-proxy versions of the
same PedsQL-Generic and Type 1 Diabetes
Module subscales completed by their chil-
dren(9,10).Additionally,theCGMsatisfac-
tion (CGM-SAT) questionnaire was
administered to the CGM group (partici-
pants and parents) at 26 weeks to assess
satisfaction with and perceived therapeutic
impact of CGM (12).
Statistical methods
Primary analysis compared treatment
groupsat26weeksusingANCOVAmod-
els, separately for adults (18 years old),
children (18 years old), and their par-
ents. Change from baseline to 26 weeks
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were adjusted for baseline values. A sec-
ondary analysis was conducted to exam-
ine QOL by frequency of CGM use.
Analyses were performed with SAS ver-
sion 9.1 (SAS Institute, Cary, NC).
RESULTS— Survey completion was
high(CGMgroup:adults98%,youth93%,
parents 97%; control group: 100, 94, and
95%, respectively). Mean A1C at enroll-
ment was 7.4% for both groups. Baseline
QOL scores were similar for the CGM and
the control group (Table 1). At 26 weeks,
there was a slight (P  0.05) improvement
favoring the CGM group for participants
18 years old for the HFS total score, HFS
behavior subscale, and the SF-12 PCS sub-
scale. There were no differences in scores
for youth or their parents for any measures
after 26 weeks. Results were similar in sub-
groups based on baseline A1C (7.0%,
7.0%) and by CGM usage (6 days/
week, 6 days/week) (online Appendix 1,
availableathttp://care.diabetesjournals.org/
cgi/content/full/dc10-0331/DC1).
CGM-SAT scores at 26 weeks were
higher than neutral (3.0 on a 5.0 point
scale) for adults, youth, and parents, with
mean  SD scores of 3.9  0.5, 3.6 
0.5,and3.80.5,respectively,andwere
higherforthosewhousedCGMmorefre-
quently (comparing CGM use 6 days/
week with use 6 days/week: mean
CGM-SAT score 4.0 vs. 3.7 for partici-
pants 18 years old, 3.8 vs. 3.4 for par-
ticipants 18 years old, and 3.9 vs. 3.7
for parents).
CONCLUSIONS— NoneoftheQOL
measures showed meaningful differences
between the CGM treatment and control
groupsafter26weeks,althoughtherewas
asuggestionofaQOLbeneﬁtfavoringthe
CGM group on a few measures among
adult participants. Lack of meaningful
differences could be due to lack of beneﬁt
of CGM use on QOL, insensitivity of the
measures to detect changes, or high base-
line levels of QOL in this population
yielding a ceiling effect. In comparing
scores on the baseline surveys with those
from population norms, we found that
adult participants had comparable scores
on the SF-12 (8) to individuals without
diabetes while scores on the PedsQL-
Generic were comparable to population
normsforchildrenwithtype1diabetesor
their parents (9). Because there is no rea-
sontobelievethatCGMimprovesQOLto
a level better than that of a disease-free
population, the amount of improvement
that could be measured in this study for
adults may have been limited by the high
QOL scores at enrollment. It is reassuring
that QOL did not decline among the par-
ticipants or parents when this new tech-
nology was initiated. Moreover, CGM-
SATscoreswerepositiveandindicativeof
substantial satisfaction with CGM.
The generalizability of these ﬁndings
shouldbeinterpretedinthecontextofthe
Table1—Baselineand26-weekvaluesforQOLandHFSmeasuresforadults(>18yearsoldatenrollment),youth(<18yearsold),andparents
of youth in the CGM and control groups
Baseline 26 weeks Comparison
CGM Control CGM Control P*
Participants 18 years
n 122 106 120 106
HFS
Total score† 37.4  12.8 37.8  14.3 33.3  11.5 36.0  13.6 0.04
Worry subscale‡ 30.1  18.3 30.6  18.3 25.3  15.8 27.7  17.3 0.12
Behavior subscale§ 46.9  11.0 47.3  13.1 43.8  11.2 46.8  13.3 0.03
PAID  22.7  15.3 21.7  18.0 18.1  14.1 18.2  14.6 0.50
SF-12
PCS¶ 54.1  5.9 54.1  7.2 55.5  4.9 54.1  6.9 0.03
MCS# 49.5  8.4 48.2  10.0 48.4  10.1 48.7  9.6 0.35
Participants 18 years
n 107** 111 103** 106
HFS worry subscale‡ 25.7  16.6 25.9  14.9 20.8  13.1 22.6  14.4 0.27
PedsQL
Generic†† 78.5  12.5 79.7  11.7 80.5  12.4 81.4  12.0 0.96
Diabetes-speciﬁc‡‡ 82.2  12.2 81.6  12.9 81.7  12.9 82.6  13.2 0.28
Parents§§
n 110 113 107 107
HFS worry subscale‡ 41.5  16.0 42.2  19.8 37.0  14.6 38.0  17.2 0.88
PAID-P¶ 46.3  14.0 43.8  15.9 47.1  12.7 43.8  17.0 0.25
PedsQL
Generic†† 76.7  11.8 77.2  13.7 76.7  12.6 77.5  13.5 0.70
Diabetes-speciﬁc‡‡ 76.0  12.1 75.7  14.2 76.5  11.6 74.6  13.3 0.28
DataaremeansSDunlessotherwiseindicated.Theseanalyseswerelimitedtosubjectsorparentswhocompletedbaselinequestionnaires.Sixchildrenrandomized
intothestudydidnotcompletebaselinequestionnairesandwereexcludedfromanalysis.*PvaluewasfromANCOVAcontrollingforbaselinevalue.†Averagescore
of all items giving equal weight to each item. Scale 0–100 with higher score denoting more fear or more likely to avoid low blood glucose. ‡Scale 0–100 with higher
scoredenotingmorefear.§Scale0–100withhigherscoredenotingmorelikelytoavoidlowbloodglucose. Scale0–100withhigherscoredenotingmoreproblems.
¶Norm-based score with higher score denoting better functioning. #Norm-based score with higher score denoting better functioning.**One participant 18 years
old in the CGM group completed only the HFS at baseline and was excluded from analyses of the PedsQL surveys at baseline (n  106) and at 26 weeks (n  102).
††Scale0–100withhigherscoredenotinghigherQOL.‡‡Scale0–100withhigherscoredenotinghigherQOL.§§Parentsrefertoparentsofparticipants18years
of age.
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who were predominantly non-Hispanic
white, well-educated, privately insured,
and most commonly treated with insulin
pumps at enrollment. These characteris-
tics may have contributed to their high
QOL scores at baseline and/or mitigated
any change in QOL associated with CGM
use. While this trial provides preliminary
insight into QOL after initiating use of
CGM, studies conducted in more socio-
demographically diverse individuals may
help to fully characterize the impact of
currentCGMuseonQOLofchildrenand
adults with type 1 diabetes.
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